FDA clears Strides Pharma’s generic Sustiva

Press enter to search
Close search
Open Menu

FDA clears Strides Pharma’s generic Sustiva

By David Salazar - 03/15/2018
Strides Pharma, a subsidiary of Bangalore, India-based Strides Shasun, has received Food and Drug Administration approval for its generic Sustiva (efavirenz). Strides is the second company to launch a generic of the HIV drug, following Mylan’s launch in February.

Strides Pharma’s generic Sustiva will be available in 600-mg dosage strength. The product has a roughly $115 million market size, according to IQVIA data.

RELATED TOPICS